Celaid Therapeutics Signed a Collaborative Research Agreement with National Cancer Center Japan

The National Cancer Center (President: Hitoshi Nakagama) and Celaid Therapeutics (President: Nobuyuki Arakawa) have signed a collaborative research agreement on the use of ex vivo expansion technology of hematopoietic stem cells for multiple myeloma.　

Three startups were selected to participate in the “Kansai Life Science Accelerator Program 2023”

Kansai Life Science Accelerator Program (KLSAP), launched in 2020, aim to support Japanese startup to expand their business overseas by providing the opportunity to participate in the mentoring sessions by expertise in the life science field.

On July 14th, the Kansai Life Science Accelerator Program 2023 pitch event was held in Kobe, and three (3) startups were selected to participate in the KLSAP2023 Accelerator Program this coming fall. The 3-month program, which includes five bi-weekly customized advisory sessions and two presentation advisory sessions, is coordinated by biomedwoRx: Life Sciences Consulting in collaboration with California Life Sciences (CLS).

MiCAN Technologies has Raised 200 Million Yen Through the Third-Party Allocation of Shares

MiCAN Technologies Inc, a member company of Kobe Biomedical Innovation Cluster (KBIC) has raised a total of 200 million JPY through the third-party allocation of shares to Real Tech Fund 3 Investment Business Limited Liability Association, Shimadzu Diagnostics Corporation and Fujimori Kogyo co. ltd.